RAD

RADIOPHARM FPO [RAD]
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Healthcare · ASX Small Cap
$0.0190 -5.0%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when RAD triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track RAD — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Drifting lower — down 5.0% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Low cash runway (4 quarters) - dilution risk
  • Low P/S ratio (2.8x)
  • Strong revenue growth (+154%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (9% of range)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (12%)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +154% — the top line is moving in the right direction
  • Altman Z-Score distress zone (0.36 < 1.81, low-confidence approx)
  • Penny stock risk ($0.019)
  • Beneish M-Score 55.78 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)
  • Trial readout: PHASE1 (est. 2026-08)

Risk Signals

  • MACD crossed bearish — momentum is fading
  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-286%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 34% over the past year
Ask Scout AI about RAD
"What's driving RAD today?" "How does RAD compare to peers?" "Key risks for RAD?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Radiopharm Receives $5.9M R&D Tax Incentive
NONE Notification regarding unquoted securities - RAD
NONE Notification of cessation of securities - RAD

Recent ASX Announcements

2026-07-03 Radiopharm Receives $5.9M R&D Tax Incentive
2026-06-30 Notification regarding unquoted securities - RAD
2026-06-30 Notification of cessation of securities - RAD
2026-06-03 Notification of cessation of securities - RAD

Key Metrics

$44.9M
Market Cap
4.5M
Avg Volume
1.1x
Vol Ratio
$0.02 — $0.04
52-Week Range
0.0%
Short Interest
N/A
Cash Runway
-92.1%
ROE
-286.2%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 105%
LLeader vs LaggardlaggardRS: -2
IInstitutional SponsorshippassInst: 12%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:RAD vs IDTRAD vs ADRRAD vs LDX
Scout Pro — Deeper Analysis for RAD
Try Pro free for 30 days
Share this analysis

Track RAD and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required